Original Source(s)
Related Content
FDA Clears Golimumab Biosimilars
New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.
May 18, 2026
-
2 min
Frontline Pharma: Sarah O’Keeffe
Ahead of HPLC 2026, Eli Lilly’s Sarah O’Keeffe reflects on leadership, collaboration, and the analytical advances helping bring increasingly complex medicines to patients
May 8, 2026
-
16 min